Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 11/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 10/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | MYT1 | Q01538 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699410 | 0.81 | CSNK1E (0.40) | CSNK1DCSNK1ECREBBP | |
| SCHEMBL16699389 | 0.76 | CASR (0.31) | CSNK1DCSNK1E | |
| SCHEMBL28975942 | 0.75 | CYP11B2 (0.39) | RIPK2HTR2A | |
| SCHEMBL30793538 | 0.74 | MEN1 (0.41) | — | |
| SCHEMBL25172258 | 0.73 | HTR2A (0.43) | RIPK2HTR2A | |
| SCHEMBL14841127 | 0.72 | HTT (0.34) | CSNK1DCSNK1ERIPK2HTR1AHTR2A | |
| SCHEMBL16698729 | 0.72 | CD38 (0.31) | — | |
| SCHEMBL16700166 | 0.72 | CASR (0.36) | CSNK1DCSNK1EPRMT5WDR77 | |
| SCHEMBL23778840 | 0.71 | AURKA (0.46) | RIPK2HTR2A | |
| SCHEMBL28975929 | 0.71 | KDM4E (0.35) | RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| CN-113039186-A | Urea 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazine active agents against hepatitis b virus HBV | 艾库里斯有限及两合公司 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247998-B2 | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | IKZF2, WEE1, NOTUM | CSNK1D 2822/4885CSNK1E 1955/4885CREBBP 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.